2025 Germany Allergy Immunotherapy Revenue Opportunities Report
Description
The 2025 Germany Allergy Immunotherapy Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in allergy immunotherapy in Germany include Merck KGaA, Stallergenes Greer, HAL Allergy Group, and Allergy Therapeutics (Bencard Allergie). Merck KGaA, headquartered in Darmstadt, Germany, is a major global player with a broad pharmaceutical portfolio that includes allergy immunotherapy products. Stallergenes Greer, based in London but active in Germany, is recognized for its allergen immunotherapies and holds a significant market share in Europe. HAL Allergy Group, based in the Netherlands, also has a strong presence in the German market offering subcutaneous and sublingual immunotherapy products. Allergy Therapeutics’ German subsidiary, Bencard Allergie, is notable for developing ultra-short course immunotherapies using modified allergens and innovative adjuvants, positioning itself strongly under new German regulatory frameworks.
Bencard Allergie, as part of Allergy Therapeutics, has become a major contributor to sales growth in Germany, generating 60% of the group’s revenues there, largely due to its novel Pollinex Quattro birch vaccine and aluminum-free MCT adjuvants that reduce treatment duration significantly. The competitive landscape also features firms like the Swiss Anergis and French DBV Technologies, but Bencard’s specialization in regulatory-compliant ultra-short immunotherapy regimes enables it to maintain a robust position. Market growth in Germany is driven by rising allergy prevalence and government-supported research, underpinned by companies investing heavily in R&D to develop personalized and efficient treatments for allergic rhinitis and asthma.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Allergy Immunotherapy by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in allergy immunotherapy in Germany include Merck KGaA, Stallergenes Greer, HAL Allergy Group, and Allergy Therapeutics (Bencard Allergie). Merck KGaA, headquartered in Darmstadt, Germany, is a major global player with a broad pharmaceutical portfolio that includes allergy immunotherapy products. Stallergenes Greer, based in London but active in Germany, is recognized for its allergen immunotherapies and holds a significant market share in Europe. HAL Allergy Group, based in the Netherlands, also has a strong presence in the German market offering subcutaneous and sublingual immunotherapy products. Allergy Therapeutics’ German subsidiary, Bencard Allergie, is notable for developing ultra-short course immunotherapies using modified allergens and innovative adjuvants, positioning itself strongly under new German regulatory frameworks.
Bencard Allergie, as part of Allergy Therapeutics, has become a major contributor to sales growth in Germany, generating 60% of the group’s revenues there, largely due to its novel Pollinex Quattro birch vaccine and aluminum-free MCT adjuvants that reduce treatment duration significantly. The competitive landscape also features firms like the Swiss Anergis and French DBV Technologies, but Bencard’s specialization in regulatory-compliant ultra-short immunotherapy regimes enables it to maintain a robust position. Market growth in Germany is driven by rising allergy prevalence and government-supported research, underpinned by companies investing heavily in R&D to develop personalized and efficient treatments for allergic rhinitis and asthma.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
